Comparative Pharmacology
Head-to-head clinical analysis: AMITID versus DESIPRAMINE HYDROCHLORIDE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMITID versus DESIPRAMINE HYDROCHLORIDE.
AMITID vs DESIPRAMINE HYDROCHLORIDE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Amitriptyline inhibits the reuptake of serotonin and norepinephrine, increasing their levels in the synaptic cleft. It also blocks histamine H1, alpha-adrenergic, and muscarinic receptors.
Inhibits reuptake of norepinephrine and serotonin at presynaptic neuronal membrane, increasing their concentrations in the synaptic cleft.
75–150 mg orally once daily at bedtime; maximum 200 mg daily. For depression, initial dose 25–75 mg/day, titrate up to 150 mg/day. For neuropathic pain, start 10–25 mg at bedtime, increase to 25–100 mg/day.
Oral: Initial 25-75 mg/day in divided doses; increase gradually to 100-200 mg/day, maximum 300 mg/day. Usual maintenance: 100-200 mg/day single or divided doses.
None Documented
None Documented
Terminal elimination half-life is 7-10 hours; clinically, steady-state is reached within 2-3 days.
Terminal half-life 12–30 hours (mean ~22 hours); extensive interindividual variability due to CYP2D6 polymorphism.
Renal: 60-80% as metabolites, <5% unchanged; Biliary/Fecal: 20-30% as metabolites.
Renal excretion of metabolites accounts for approximately 70%; fecal elimination ~30%. Unchanged drug <5% in urine.
Category C
Category C
Tricyclic Antidepressant
Tricyclic Antidepressant